Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
109,628,845
-
Total 13F shares
-
65,029
-
Share change
-
-37,415
-
Total reported value
-
$785,731
-
Price per share
-
$12.08
-
Number of holders
-
9
-
Value change
-
-$524,304
-
Number of buys
-
4
-
Number of sells
-
3
Institutional Holders of Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) as of Q4 2025
As of 31 Dec 2025,
Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) was held by
9 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
65,029 shares.
The largest 9 holders included
PARSONS CAPITAL MANAGEMENT INC/RI, SG Americas Securities, LLC, Premier Path Wealth Partners, LLC, NISA INVESTMENT ADVISORS, LLC, Westfuller Advisors, LLC, GAMMA Investing LLC, MassMutual Private Wealth & Trust, FSB, Catherine Avery Investment Management LLC, and FINANCIAL CONSULATE, INC.
This page lists
9
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.